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Triggering necroptosis in cisplatin and IAP antagonist-
resistant ovarian carcinoma
KE McCabe1,4, K Bacos1,4, D Lu1,2,4, JR Delaney1, J Axelrod1, MD Potter1, M Vamos3, V Wong1, NDP Cosford3, R Xiang2 and
DG Stupack*,1
Ovarian cancer patients are typically treated with carboplatin and paclitaxel, but suffer a high rate of relapse with recalcitrant
disease. This challenge has fostered the development of novel approaches to treatment, including antagonists of the ‘inhibitor of
apoptosis proteins’ (IAPs), also called SMAC mimetics, as apoptosis-inducing agents whose action is opposed by caspase
inhibitors. Surprisingly, IAP antagonist plus caspase inhibitor (IZ) treatment selectively induced a tumor necrosis factor-α (TNFα)-
dependent death among several apoptosis-resistant cell lines and patient xenografts. The induction of necroptosis was common
in ovarian cancer, with expression of catalytically active receptor-interacting protein kinase-3 (RIPK3) necessary for death, and in
fact sufficient to compromise survival of RIPK3-negative, necroptosis-resistant ovarian cancer cells. The formation of a
necrosome-like complex with a second critical effector, receptor-interacting serine–threonine kinase-1 (RIPK1), was observed.
RIPK1, RIPK3 and TNFα were required for the induction of death, as agents that inhibit the function of any of these targets
prevented cell death. Abundant RIPK3 transcript is common in serous ovarian cancers, suggesting that further evaluation and
targeting of this RIPK3-dependent pathway may be of clinical benefit.
Cell Death and Disease (2014) 5, e1496; doi:10.1038/cddis.2014.448; published online 30 October 2014
Comprising only 3% of all cancer cases in women in the United
States, ovarian cancer is nonetheless the fifth leading cause of
cancer-specific mortality.1 Approximately 90% of ovarian
cancers are epithelial cancers derived from ovarian surface
or fallopian tube epithelium.2 Serous ovarian carcinoma is the
most common histologic subtype, with high-grade serous
ovarian cancer (HGSOC) the most aggressive subtype,
constituting 90% of these cases.3 Owing to its predominance
and lethal nature, HGSOC is the most widely researched type
of ovarian cancer.3
Typical treatment of HGSOC includes initial surgical
debulking and subsequent systemic or intraperitoneal
carboplatin and paclitaxel. While many tumors initially
respond, 60–85% of patients experience disease recurrence
following primary therapy.1,3 Relapse is often accompanied by
disease that has acquired resistance to these drugs. One
mechanism implicated in recurrence is the evasion of
apoptosis, a form of programmed cell death whose loss
represents an established hallmark of cancer.4 Exploiting
alternative cell death pathways, including necroptosis
(‘programmed necrosis’), may offer an alternative strategy to
treat such recurrent disease.5
The cellular inhibitor of apoptosis proteins (c-IAP1 and
c-IAP2) represent promising targets for therapy, as they are
overexpressed in many cancers and have important roles in
both apoptotic and necroptotic death pathways.6 Upon binding
of tumor necrosis factor α (TNFα) to TNFα receptor 1, the
adaptor protein TRADD (tumor necrosis factor receptor type
1-associated death domain protein) is recruited to the
cytosolic death domain of TNFα receptor 1.7 This facilitates
subsequent receptor-interacting protein kinase-1 (RIPK1)8
and TRAF2/5 (TNF receptor-associated factor 2/5) binding,9
which leads to cellular inhibitor of apoptosis protein 1/2
(c-IAP1/2) recruitment. The formation of this TNFα-induced
membrane-associated complex, known as complex I, results
in NF-κB (nuclear factor-κ-light-chain-enhancer of activated B
cells) activation, apoptosis or necroptosis, depending on the
proceeding intracellular signaling events.
Ubiquitination of RIPK1 by the E3 ligase c-IAP1/2 activates
the canonical NF-κB pathway, resulting in cell survival.10
Conversely, the deubiquitination of RIPK1 or, alternatively, the
lackof ubiquitination following IAPantagonist (IAPa or I)-induced
degradation of c-IAP1/2 leads to the formation of a cytosolic
complex that includes FADD (Fas-associated protein with death
domain) and caspase-8. This triggers apoptosis if caspases are
active (complex IIa), or receptor-interacting serine–threonine
kinase-3 (RIPK3)-dependent necroptosis in the presence of
caspase inhibitors (complex IIb; necrosome).11,12
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IAPa will induce apoptosis in specific triple-negative breast
or ovarian cancer cell lines,13–15 an observation that supports
the launch of NCT01681368: A Phase II trial of the IAP
antagonist Birinipant for advanced ovarian, fallopian tube, and
peritoneal cancer (http://www.clinicaltrials.gov). In contrast,
activation of TNFα-dependent necroptosis via IAPantagonism
has been demonstrated in a colon cancer cell line,16 although
not in other carcinomas.
The triggering of necroptotic signaling among ovarian
cancer cells could have important therapeutic implications.
Here, we demonstrate that IAP antagonism, in the presence of
a caspase inhibitor, triggers necroptosis in apoptosis-resistant
ovarian cancer cells, and, moreover, that patient-derived
tumor cells display sensitivity to this treatment. Activation of
this death pathway was dependent on the kinase activity of
RIPK3, and required RIPK1, both of which we show are
frequently expressed in serous ovarian cancer, as well as the
cytokine TNFα. Notably, this death pathway occurred selec-
tively in apoptosis-resistant cells. The results suggest a
common functional necroptosis pathway that might be
exploited in future therapeutic designs.
Results
Treatment with IAPa and the protease inhibitor zVAD
induces death of RIPK3-expressing ovarian cancer cells.
A panel of human ovarian cancer cell lines were screened for
the induction of apoptosis or necroptosis (as depicted in
Figure 1a), following treatment with IAPa.14 Supporting the
impetus to move IAPa forward in clinical trials, two of these
(OVCAR4 and SKOV-3) showed some sensitivity to IAPa as a
single agent (Figure 1b and He et al.11). This was at least
partially blocked by the inhibitor of apoptosis z-VAD-fmk
(pancaspase inhibitor, Z-Val-Ala-DL-Asp-FMK, Z) IAPa plus
zVAD; IZ, which selectively, but not exclusively, inhibits
caspase activity. Importantly, and perhaps not surprisingly,
the majority of tumor lines tested showed resistance to the
induction of apoptosis by either IAPa (Figure 1b: Hey,
OVCAR5 and OVCAR3; not shown: IGROV1) or cisplatin
(Supplementary Figure 1a). Neither caspase-8 nor FADD
appeared to be limiting for apoptosis (Figure 1c). Indeed, the
cells with the lowest expression of FADD were the most
sensitive to the induction of apoptosis by IAP antagonism.
Interestingly, zVAD treatment actually promoted, rather than
rescued, death in some cell lines (Figure 1b, bottom panels).
This raised the possibility of the induction of an alternative form
of programmed cell death: necroptosis. This notion was
bolstered by the observation that apoptosis-resistant but IAP
antagonist plus caspase inhibitor (IZ)-sensitive lines exhibited
expression of RIPK3 (Figures 1b and c), a critical regulator of
necrotic cell death.11 Further supporting this possibility, cell
death induced by IZ was not accompanied by the activation of
caspases, as occurs during apoptosis (Figure 1d).6 As the
concept that tumor cells (in particular serous ovarian tumor
cells) might be sensitive to necroptosis had not been
previously explored, we characterized this cell death further.
Formation of the necrosome in IZ-sensitive cells. It
remained possible that necrosis occurred as a default
pathway when IAPa were ineffective at inducing the
clearance of IAPs required for apoptosis.13 To test this, we
first evaluated the presence of two IAPs (c-IAP1 and c-IAP2)
following antagonist treatment (Figure 2a). As shown, IAPa
treatment resulted in the complete and persistent loss of
cIAPs within minutes. Thus, IAP loss is consistent with
necroptotic death. However, a general loss of all IAPs was not
observed, as treatment did not appear to influence the
expression of X-linked inhibitor of apoptosis (XIAP)
(Figure 2b). A third target of IAPa, ML-IAP (a member of
IAP family, containing a single copy of a baculovirus IAP
repeat (BIR) as well as a RING-type zinc-finger domain), was
not expressed in these cells (Supplementary Figure 1b).
To evaluate whether a functional necrosome complex was
indeed forming, we next immunoprecipitated RIPK3
expressed in the ovarian cancer cells and tested for the
presence of associated proteins. IZ treatment resulted in the
formation of a complex with abundant representation of
RIPK1, but with much lower levels of FADD and caspase-8
(Figure 2c). Treatment with either agent alone (I or Z) did not
result in the formation of a complex (Figure 2c). In contrast,
mixed lineage kinase domain-like (MLKL) was constitutively
associated with RIPK3 under all three conditions (Figure 2d).
As formation of the necrosome promotes the phosphorylation
of MLKL as a downstream effector of RIPK3, we next
confirmed that IZ treatment did, in fact, result in marked
phosphorylation of MLKL (Figure 2e). In fact, simple ectopic
expression of RIPK3 led to a lower basal level of MLKL
phosphorylation, although this was insufficient to induce
cell death.
Further supporting a model of classical RIPK1-dependent
necroptosis, IZ-induced death was rescued by the inclusion of
necrostatin-1, a RIPK1 inhibitor17 (Figure 2f). Cell death was
alternatively also blocked by inclusion of necrosulfonamide
(Figure 2f), which targets the death-inducing RIPK3 substrate,
MLKL.18 These results, together, suggest that necroptosis is
induced by activation of RIPK1 followed by activation of RIPK3
and MLKL in ovarian cancer cells.
RIPK1 expression is required for IZ-induced death of
ovarian cancer cells. All of the ovarian cancer tumor cell
lines examined expressed RIPK1, and its expression was not
sufficient for, or predictive of, cell death following I or IZ
treatment (Figure 1b). As necrostatin-1 inhibited cell death,
we next silenced RIPK1 expression (Figure 3a, inset) and
then evaluated cell survival following exposure to IZ. As
shown, the loss of RIPK1 was protective, consistent with the
necrostatin sensitivity of the death pathway (Figure 3a). By
contrast, the knockdown of the adaptor protein FADD had a
more modest effect (Figure 3b), suggesting that FADD may
provide some facilitating role in necroptosis in the ovarian
cancer cells, yet was not critical in facilitating RIPK1 to RIPK3
signaling.
RIPK3, but not an inactive mutant, promotes IZ-induced
death. To more carefully characterize the requirement for
RIPK3, we next used genetic approaches to reconstitute
RIPK3 expression in the RIPK-deficient, death-resistant HEY
cells (Figures 1b and c) and to suppress RIPK3 expression in
the death-inducible OVCAR3 cells. In agreement with the
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capacity of necrostatin to block IZ-induced death, the
expression of RIPK3, but not a kinase dead RIPK3 mutant,
was sufficient to confer sensitivity to IZ-induced death among
HEY cells (Figure 4a). The expression level of the kinase
dead version was, however, somewhat lower than that of the
wild-type kinase, possibly due to other recently described
death-inducing effects of catalytically compromised RIPK3.19
Selection of clones of HEY with much lower expression of
RIPK3 similarly resulted in cell death following IZ treatment
(Figure 4b), suggesting that relatively low levels of RIPK3
may be sufficient to confer sensitivity. In agreement with
these observations, the loss of RIPK3 expression compro-
mised cell death in IZ-sensitive cell lines (Figure 4c). Thus,
RIPK3 expression is a prerequisite for this cellular death
pathway.
IZ treatment promotes autocrine TNFα production. The
TNFα receptor I must be activated by ligation and subsequent
formation of the membrane-associated complex I (depicted in
Figure 1a) for the necrosome to form and lead to necrotic cell
death. We reasoned that without exogenous death receptor
ligand, IZ-sensitive ovarian cancer cells might have to
produce their own extrinsic death pathway stimulus. The
relative TNFα mRNA levels in I- or Z-only treated cells was
comparable to levels in vehicle-treated cells; however, a
marked upregulation of TNFα was observed in IZ-treated
OVCAR3 cells (Figure 5a), which was dependent on the
expression of RIPK1 (Figure 5b). Ectopic expression of
RIPK3 rescued IZ-induced TNFα in HEY cells (Figure 5c),
suggesting that RIPK3 expression may enhance autocrine
TNFα production by the ovarian cancer cells as it does in
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Figure 1 Activation of death pathways in ovarian cancer cells. (a) In the presence of IAP antagonism, TNFα receptor-mediated signaling can lead to apoptosis, or, in the
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myeloid cells.20 The kinase activity of RIPK3 was critical for
this effect, as the expression of catalytically dead RIPK3
(K50A) did not induced the expression of TNFα (Figure 5c).
TNFα appeared to be required for death, as a TNFα-
neutralizing antibody was able to rescue cell survival in
ovarian carcinomas expressing endogenous (Figure 5d) or
ectopic (Figure 5e) RIPK3.
RIPK3 expression in ovarian cancer. Although RIPK3
expression promotes necroptosis, we only noted the expres-
sion of RIPK3 in a few ovarian cancer cell lines. This raised
the question as to what the relative expression of RIPK3 in
ovarian tumors might be. We focused on serous ovarian
cancer, which is well curated in the The Cancer Genome
Atlas repository and also accounts for the greatest overall
mortality among ovarian carcinoma patients. The database
cataloged an enrichment for RIPK3 expression in serous
ovarian cancer (Figure 6a). In fact, more than three-quarters
of serous ovarian tumors expressed RIPK3 levels above the
mean expression established across all tumors. Almost half
of tumors were enriched at least twofold over the mean
expression, as opposed to only one in six tumors, which was
twofold or less below the mean (Figure 6a). As we had
previously observed in the OVCAR3 cells, and consistent
with the TCGA data set, our two cisplatin-resistant patient-
derived tumor cells (OV no. 2224 and OV no. 3971) revealed
RIPK3 protein expression upon immunoblot analysis
(Figure 6b). Moreover, the patient-derived tumor cells
demonstrated IZ-induced autocrine expression of TNFα
(Figure 6c). Accordingly, we observed no induction of
apoptosis with IAP antagonism alone, but IZ-induced cell
death (Figure 6d) that was blocked by TNFα-neutralizing
antibody (Figures 6e and f). Altogether, the results support a
model in which necroptotic cell death is common following
IAP antagonism.
Discussion
The poor prognosis for patients with advanced ovarian cancer,
combined with the universal loss of tumor protein p53 (TP53)
in an otherwisemolecular heterogeneous background, has led
to increasingly innovative approaches to treat the disease.
Although 70–80% of disease will respond to initial chemo-
therapy, recurrence of recalcitrant disease is common.
Interestingly, the IZ-sensitive patient tumor cells used here
also exhibited quite high cisplatin resistance (half-maximal
inhibitory concentration 410 μM). This observation in parti-
cular would appear to support the development of agents,
such as Birinipant, that antagonize IAPs as adjuvants to
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existing therapies to prevent the selection of cisplatin
resistance in tumors.
We examined several ovarian cell lines for their ability to
undergo death following IAPa treatment. This was important,
as attention has recently focused on the suitability of
commonly used cell lines as models for serous ovarian
cancer. Domcke et al.1 assessed the genetic similarity
between commonly used ovarian cancer cell lines and serous
ovarian tumor tissue samples to determine the likelihood of
each cell line being of HGSOC origin. Interestingly, while the
OVCAR3 cell line we study here was found to be similar to the
general tumor tissue signature in this study, the other ovarian
cancer cell lines that remain part of the NCI-60, such as HEY
and SKOV-3, were not. Perhaps more importantly, the
molecular signature of cell death proteins and the response
to antagonism revealed that OVCAR3 cells were quite similar
to patient-derived tumor cells typified by OV#2224 and
OV#3871, and thus acted as a representative cell line for
this system. Indeed, the cisplatin-resistant OVCAR3 may
represent a preferred cell line for the analysis of emerging
ovarian cancer treatments.
We demonstrate that TNFα production is required to trigger
necroptosis in the ovarian cancer cells, and that RIPK3
enhanced this process. Consistent with recent reports,
depletion of RIPK3 has a marked impact on the induction of
necrosis,16 and notably, the expression of RIPK3 was
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sufficient to restore sensitivity to necroptosis in the apoptosis
and necroptosis-resistant HEY cells. This required the
production of TNFα, as antibodies to TNFα prevented IZ-
mediated killing. Nonetheless, the IZ combination elicits
additional effects, as simple addition of TNFα to either I or Z
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alone was not sufficient to promote cell death (KM, DGS,
unpublished observations).
In these studies, the source of TNFα was autocrine.
However, caution is warranted in overinterpreting this require-
ment in vivo, as TNFα can be produced by stromal or
inflammatory cells in the tumor microenvironment.21 In this
case, the in vivo use of IAPa that are thought to induce
effectively apoptosis in patients might rather be effecting cell
death by necroptosis. The requirements for, and the form of
death may be important to understand in the clinical setting. In
fact, understanding the type of death induced by an agent
in vivo is more than just a semantic distinction. Increasingly,
molecular determinants are used for the stratification of
patients into preferred treatment groups. This is progressing
rapidly, and the initial single gene requirements for patient
stratification22 are destined to become a thing of the past,
yielding to more complex algorithms for personalized
medicine.23 Thus, the question raised by the current studies,
that is, whether tumor cells undergo apoptosis or necroptosis
in vivo following exposure to IAPs, becomes a key factor for the
implementation of therapy, and should be addressed in future
directed studies.
Materials and Methods
Reagents. IAPa were synthesized by Mitchell Vamos (Sanford-Burnham Medical
Research Institute, La Jolla, CA, USA). The pancaspase inhibitor zVAD-fmk was
purchased from Bachem (Torrance, CA, USA) (N-1510.0005BA). Necrostatin-1
(2324/10) and necrosulfonamide (432531-71-0) were purchased from R&D Systems
(Minneapolis, MN, USA) and EMD Millipore (Temecula, CA, USA), respectively. The
TNFα-neutralizing antibody was purchased from Cell Signaling Technology
(Danvers, MA, USA; 7321). The following primary antibodies were used for
western blotting: c-IAP1 (Cell Signaling Technology; 7065), c-IAP2 (Cell Signaling
Technology; 3130), RIPK3 (Cell Signaling Technology; 12107), RIPK1 (Cell
Signaling Technology; 3493), caspase-8 (BD Biosciences; 551242), FADD (BD
Biosciences; 610399), p62 (BD Biosciences; 610832), LC3 (Novus Biologicals,
Littleton, CO, USA; NB100-2220), β-actin (Sigma, St. Louis, MO, USA; A5441),
PARP (BD Biosciences; 51-6639GR), caspase-3 (Cell Signaling Technology; 9668),
caspase-7 (Cell Signaling Technology; 9492), XIAP (Cell Signaling Technology;
5471), MLKL (EMD Millipore; MAB C604), phospho-MLKL (Abcam, Vancouver, BC,
USA; Ab187091) and α-tubulin (EMD Millipore; CP06). The following horseradish
peroxidase-conjugated secondary antibodies were used for western blotting: goat
anti-rabbit IgG (H+L) (Jackson ImmunoResearch, Bar Habor, ME, USA; 111-035-
003), goat anti-mouse IgG (H+L) (Jackson ImmunoResearch; 115-035-003), goat
anti-rabbit IgG, Fc fragment-specific (Jackson ImmunoResearch; 111-035-008) and
mouse anti-rabbit IgG, light-chain-specific (Jackson ImmunoResearch; 211-032-
171). The anti-mCherry antibody used for immunoprecipitation was generated in-
house by immunization of rabbits with full-length mCherry and immunoaffinity
purification of immune serum on a Sephadex-mCherry column.
Cell culture. OV no. 2224 and OV no. 3971 cells were isolated from ovarian
cancer patients, subcultured12 and passaged through mice. Informed consent was
obtained to use these cells for research purposes. The human ovarian cancer cell
lines HEY, OVCAR3, OVCAR4, OVCAR5 and SKOV-3 were maintained in no-
glucose RPMI-1640 (Mediatech Inc., Manassas, VA, USA) supplemented with 1 g/l
glucose, 10% FBS, MEM nonessential amino acids and 1 mM sodium pyruvate
(Mediatech Inc.). All cells were maintained in an incubator set to 37 °C and 5% CO2.
Generation of stable cell lines. All stable cell lines were generated by
using lentiviral-based RNAi or lentiviral-based gene expression systems, as
described previously.24 Briefly, shRIPK3 and shRIPK1 cell lines were selected for
with 1 μg/ml puromycin after being infected with lentivirus containing shRNA
constructs specifically targeting RIPK3 or RIPK1 mRNA. Cell lines (OVCAR3 and
HEY) stably expressing mCherry-tagged RIPK3 or a kinase dead mutant (K50A)
were selected with 1 μg/ml puromycin following lentivirus treatment with a pLV
RIPK3-mCherry plasmid.
IAP antagonism time-course assay. Cells were seeded into the wells of
6-well plates (2 × 106 cells/well) and allowed to adhere for ~ 16 h at 37 °C before the
addition of drug(s). Media were replaced with fresh media containing 1 μM IAPa and
cells were incubated at 37 °C for various amounts of time. At selected time points,
media were aspirated and cells were washed two times with PBS and lysed with
150 μl RIPA lysis buffer supplemented with a protease inhibitor cocktail (Sigma),
2 mM sodium orthovanadate and 50 mM NaF. Cells were collected using a cell lifter
(Thermo Fisher, Waltham, MA, USA), transferred to an Eppendorf tube, passed
through a pipet tip five times and incubated on ice for 10 min. The lysate was
centrifuged at 14 000 × g for 5 min at 4 °C, and the supernatant (lysate) was
collected and stored at − 20 °C until western blot analysis.
Growth inhibition assay. Cells were seeded into wells of a 96-well plate
(104 cells/well; 100 μl final volume) and allowed to adhere for ~ 16 h at 37 °C before
the addition of drug(s). Treatment or vehicle was added in a total dosage volume of
11 μl (to final concentrations of 10 μM necrostatin, 2 μM necrosulfonamide, 20 μM
zVAD-fmk or 1 μM IAPa). Cells were incubated at 37 °C for 48 h, washed gently two
times with 100 μl PBS and stained with 75 μl crystal violet (Sigma) aqueous dye
solution (0.1% crystal violet, 150 mM NaCl, 20% methanol) for 25 min at room
temperature. Stain was removed and cells were washed two times with water to
remove unbound dye, and then allowed to dry. Cell-bound crystal violet was
resolubilized with 75 μl methanol and A600 was measured using a PowerWave XS2
Microplate Spectrophotometer (BioTek). All treatment conditions were assayed in
triplicate and plotted as mean±S.D. Except as noted, all experiments were
performed three or more times with similar results. ‘Cell loss’ was calculated using
the formula: 100− ((A600 treatment/A600 vehicle) × 100).
Immunoprecipitation. For the immunoprecipitation of mCherry-tagged
RIPK3, cells were lysed with ‘NP-40 Alternative Lysis’ (NAL) buffer (EMD Millipore;
492016) buffer (100 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40 Alternative) following
24 h exposure to the indicated agents. Cell mixtures were centrifuged at 2500 × g for
3 min, then total protein concentration was determined as described and 1 mg
protein was diluted with lysis buffer to a final volume of 1 ml. Lysates were incubated
with 5 μg rabbit anti-mCherry antibody for ~ 16 h at 4 °C, followed by 20 μl Protein
A/G resin (G-Biosciences, St. Louis, MO, USA) for ~ 3 h at 4 °C. Following
centrifugation at 2500 × g for 3 min, resin was washed four times with NP-40
Alternative wash buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% NP-40
Alternative). Immunoprecipitates were eluted by heating in reducing sample buffer
for 5 min at 100 °C, cooled to room temperature and briefly centrifuged to pellet
beads. Supernatants were analyzed by SDS-PAGE and subjected to immunoblot
analysis.
Immunoblot analysis. Cell lysates were generated using NP-40 Alternative
Lysis buffer, as described above, when cells reached ~ 75% confluence. In
treatment cases, untreated cells or cells treated following a 24 h incubation with
indicated agents were lysed as described above. Total protein concentration was
determined using the Micro BCA Protein Assay Kit (Thermo Scientific, Rockford, IL,
USA), and 30 μg lysate was loaded onto 10% SDS-PAGE gels, resolved and
transferred to PVDF membrane (Bio-Rad). Following incubation with 5% milk/0.1%
Tween 20 (Thermo Fisher)/TBS blocking buffer, membranes were subjected to
immunoblotting. Western blots were incubated with Super Signal West Pico
Chemiluminescent Substrate (Thermo Scientific) or Super Signal West Dura
Chemiluminescent Substrate (Thermo Scientific) exposed to film, and the film was
developed.
Quantitative PCR. Cells were seeded into wells of a 6-well plate (2 × 106 cells/
well) and allowed to adhere for ~ 16 h at 37 °C before the addition of agents. Media
were replaced with 1 ml fresh media containing treatment or vehicle, and cells were
incubated at 37 °C for 48 h. Media were aspirated, and cells were washed with PBS
and incubated with 0.5 ml trypsin for several minutes at 37 °C. An equal volume of
media were added to each well and cells were transferred to Eppendorf tubes and
centrifuged at 1000 × g for 5 min. The supernatant was aspirated and RNA was
extracted using a NucleoSpin RNA Kit (Macherey-Nagel, Bethlehem, PA, USA)
according to the manufacturer’s instructions. RNA concentration was determined by
measuring A260, and SuperScript III First-Strand Synthesis System for RT-PCR
(Invitrogen) was used to synthesize cDNA from 1 μg RNA. Quantitative PCR was
performed using a 1 : 10 dilution of generated cDNA, primers specific for human
actin and TNFα, LightCycler 480 SYBR Green I Master (Roche, South San
Francisco, CA, USA) and a LightCycler 480 Instrument (Roche).
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Statistics. Data highlighted as significant, as indicated with an asterisk (*) in
each figure, were determined in all cases by Student’s T-test. The threshold for
significance in all cases was set with a probability of o0.05.
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